Previous 10 | Next 10 |
Amarin ( AMRN ) is fast approaching a significant event as the company’s lawsuit against a couple of generic drug makers is scheduled for trial on January 13, 2020. The main counter parties in this case are Dr. Reddy’s Laboratories (RDY), Hikma Pharmaceuticals (HKMPF) and Teva (T...
2019 finishes with an extra kick for investors. Part of that is the continued strong run of the market, erasing memories of last year's near bear market and extending the decade-long bull. There also are plenty of market headlines and events that have sprung over the end of the year, from Ph...
Investing in the best growth stocks can generate superior returns over the long term. On the other hand, growth stocks are also particularly volatile and risky. The key, like usually happens, is separating the fundamentally sound companies from the ones with mediocre fundamentals. The follow...
When asked recently about which biopharmaceutical companies will be the most likely takeout targets in 2020, analysts at J.P. Morgan were most enthusiastic about Uniqure (NASDAQ: QURE) , Amarin (NASDAQ: AMRN) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . What ...
Sure, there was a little intrigue along the way. But the outcome that pretty much everyone expected arrived: Amarin (NASDAQ: AMRN) won FDA approval of a key label expansion for Vascepa. The drug, first approved in 2012 for lowering triglyceride levels, is now also approved to reduce cardiova...
What is the company doing to maintain or improve its profit margin? - Phillip Fisher I once read that patience is one of the most powerful virtues because its power grows irresistible with time. Now if you're a shareholder of Intercept Pharmaceuticals ( ICPT ) who didn't sell out this ...
Matinas BioPharma 's (NYSEMKT: MTNB) shares slipped 13.4% on Monday. This came after Amarin Corp. (NASDAQ: AMRN) secured approval from the Food and Drug Administration to include a cardiovascular outcomes benefit on the prescription label for Amarin's purified omega-3 drug, Vascepa. Am...
Trading in shares of Amarin (NASDAQ: AMRN) was halted on Friday when the stock started to take off in anticipation of good news from the U.S. Food and Drug Administration. Later in the day, the FDA provided an early holiday present to Amarin investors: the revised label the company had ...
Citing valuation and litigation risks, Stifel's Derek Archila has downgraded Amarin ( AMRN +0.6% ) to Hold with a $28 (15% upside) price target. More news on: Amarin Corporation plc, Healthcare stocks news, Read more ...
Shares of Amarin (NASDAQ: AMRN) jumped by as much as 11.7% in pre-market trading Monday morning. What's driving this sizable move higher ahead of the opening bell? On Friday, Amarin announced that the Food and Drug Administration had approved Vascepa as an add-on to statin therapy in patien...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...